All-trans retinoic acid (ATRA) induces clinical remission in patients with t(15;17) acute promyelocytic leukemia (APL) carrying leukemogenic promyelocytic leukemia-retinoic acid receptor A (PML-RARA) fusion protein by overcoming PML-RARA transcriptional repression and inducing myeloid differentiation. To identify more potent chemical differentiation inducers, a screening assay was developed utilizing an ATRA-insensitive NB4 cell line (NB4-c) in which differentiation could be measured after 48 hours when primed with ATRA followed by other potential inducers. Over 300 cytostatic agents selected from the National Cancer Institute library were screened using this established method. Three compounds, NSC656243, NSC625748, and NSC144168, were identified to amplify ATRA-induced differentiation with acceptable cytotoxicity in NB4-c cells. In the absence of ATRA, these compounds also induced HL-60 and murine erythroleukemia cells to undergo partial differentiation. NSC656243, a benzodithiophene compound, was selected for further studies to examine the underlying mechanism of action. The differentiation effect of NSC656243 was associated with enhanced ATRA-mediated up-regulation of cell cycle regulatory proteins p21 waf1 and p27 kip1 , retinoblastoma dephosphorylation, expression of RIG-E and RIG-G, and myelomonocytic differentiation-specific down-regulation of the myeloperoxidase (MPO) gene. Moreover, at 2-to 3-fold higher concentrations than those used to synergize with ATRA, NSC656243 induced apoptosis in NB4-c cells by reactive oxygen species-mediated pathways. The dual effects of benzodithiophenes (i.e., differentiation and apoptosis induction) support further development of these compounds as therapeutic agents for leukemia. (Cancer Res 2005; 65(17): 7847-55) 
Introduction
Treatment with all-trans retinoic acid (ATRA), a normal metabolite of vitamin A, in combination with chemotherapy, results in clinical remission in acute promyelocytic leukemia (APL) patients with t(15;17) translocation that encodes the promyelocytic leukemia-retinoic acid receptor a (PML-RARa) leukemogenic fusion protein (1) (2) (3) . PML-RARa is a dominant repressor of normal RARa function and blocks granulocytic differentiation (4, 5) . It has been found that PML-RARa binds to the RARa nuclear receptor corepressors SMRT, N-CoR, and histone deacetylase more tightly than wild-type RARa and, therefore, cannot be dissociated by physiologic ATRA concentrations (6) (7) (8) (9) . However, pharmacologic ATRA concentrations dissociate the corepressors from PML-RARa and overcome PML-RARa transcriptional repression (7, 8) . Inhibitors of histone deacetylase, such as trichostatin A and butyrates, synergize with ATRA-mediated differentiation in APL cells; phenylbutyrate, in combination with ATRA treatment, induced clinical remission in one patient with APL in ATRAresistant relapse (10, 11) . However, preclinical research predicts that high (mmol/L) concentrations with currently used inhibitors of histone deacetylase, such as phenylbutyrate or valproic acid, will be required to reach a therapeutic effect (12) (13) (14) . Therefore, identification of more potent agents to enhance ATRA-induced differentiation is needed. Previously, we reported that APL t(15;17) NB4 cells are induced to differentiate by ATRA but not by nonretinoid inducers (15) . However, ATRA-induced differentiation is amplified and more rapid when combined with various nonretinoid chemical differentiation inducers (15) . This synergism is termed superinduction of differentiation and considered a desirable therapeutic goal. A rapid (24-48 hours) assay was established to screen for compounds that enhance ATRA-induced differentiation. Three hundred and seventy-one cytostatic agents were selected from the National Cancer Institute (NCI) library and screened. Three compounds, NSC656243 (4,8-dioxo-benzo[1,2-b:5,4-bV]dithiophene-2-carboxylix acid), NSC625748 (3,6-bis[1-azetidinyl]-1,2,4,5-tetrazine), and NSC144168 (3-bromomethyl-2[1H]-quinoxalinone), at low Amol/L concentrations, were identified to enhance ATRA-induced differentiation of NB4-c cells. Moreover, these agents were also able to partially induce HL-60 and murine erythroleukemia cell differentiation in the absence of ATRA priming. We further evaluated NSC656243, a benzodithiophene (16, 17) , which was the most potent differentiation inducer and induced apoptosis at 2-to 3-fold higher concentrations.
were passaged in late log phase; for each experiment, there was preseeding to maintain log phase.
Screening assay for differentiation inducers. Compounds were selected for study from the NCI library of compounds previously evaluated in the 60-cancer cell line program. Three hundred and seventy-one cytostatic compounds, identified as those that maintained multilog activity between 30% and 60% growth inhibition in the 48-hour NCI screening assay, were selected on the basis of stability, solubility, and availability. NB4-c cells were primed with ATRA (0.5 Amol/L for 1 hour), washed, resuspended, and distributed into 96-well plates at 60,000 cells per well. Negative and positive controls were NB4-c cells treated with 0.5 Amol/L ATRA alone or ATRA + 2 mmol/L hexamethylene bisacetamide (HMBA), respectively, as described previously (15) . Compounds to be tested were added at the estimated 50% growth inhibitory concentration (GI 50 ) or at a 10-fold dilution of the GI 50 concentration. The plates were incubated at 37jC for 48 hours; during this time, they were checked for gross contamination and the presence of precipitated drug. After incubation, they were centrifuged at 1,700 rpm for 10 minutes, the drug-containing media was aspirated, and differentiation induction was assayed by adding 200 AL of media containing 20 AL per stock nitroblue tetrazolium (NBT) and 1 AL/mL tetradecanoylphorbol acetate and incubating for 25 minutes. Following centrifugation, the NBT media was removed and 200 AL of 10% SDS/0.4 NH 4 Cl warmed to 70jC were added to each well. The plates were read on a Bio-Tek reader using 750 nm filters. The plates were then placed in the À70jC freezer. To assay toxicity, the plates were removed and placed into a 60jC oven for 2 hours. Fifty microliters of propidium iodide (PI) were added and incubated in the dark for 2 hours. PI was able to penetrate intact cells as a result of freezing. The plates were read on a Millipore fluorescence reader with filter set at EX530/25 and EM 620-40. The association between induction of differentiation and growth inhibitory effects of the compounds was calculated using the ratio of NBT/PI measured in cells treated with drug + ATRA and compared with that of cells treated with ATRA alone. A test compound was considered effective if at Amol/L concentration, the enhancement of ATRA differentiation was equal or superior to that induced by HMBA, and growth inhibition was <65%. Several of these compounds, including HMBA, were submitted for blind, independent assessment of growth inhibition, cytotoxicity, and differentiation in a 5-day assay by using regular methods described below. The integrity of this rapid screening assay was confirmed because the same lead compounds were identified using more complete 5-day differentiation assay.
Nonscreening assessment of toxicity and differentiation. The percentage of viable cells after treatment was determined by trypan blue exclusion. Myeloid differentiation of HL-60 and NB4-c cells was determined by NBT reduction assay as described before (21) . Erythroid differentiation of murine erythroleukemia cells was determined by benzidine staining assay for hemoglobin as described before (22) .
Western blot analysis. Protein extracts (50 Ag), prepared with radioimmunoprecipitation assay lysis buffer [50 mmol/L Tris-HCl, 150 mmol/L NaCl, 0.1% SDS, 1% NP40, 0.5% sodium deoxycholate, 1 mmol/L phenylmethylsulfonyl fluoride, 100 mmol/L leupeptin, and 2 Ag/mL aprotinin (pH 8.0)], were separated on a 8% or 12% SDS-polyacrylamide gel and transferred to nitrocellulose membranes. The membranes were stained with 0.2% Ponceau S red to assure equal protein loading and transfer. After blocking with 5% nonfat milk, the membranes were incubated with antibodies to p27 kip , p21 waf1 , retinoblastoma, Bcl-2, and poly(ADP-ribose) polymerase (PARP; Oncogene, Co., San Diego, CA) proteins. The immunocomplex was visualized by chemiluminescence.
Northern blot analysis. Total RNA was isolated with RNAzol B (Bioctax) from 10 6 cells. Twenty micrograms RNA was sized fractionated on a 1.2% agarose-2.2 mol/L formaldehyde gel, transferred to hybrid-N+ membrane (Amersham, Piscataway, NJ) in 20Â SSC, and UV cross-linked (Stratalinker). RIG-E and RIG-G cDNAs were cloned as in our previous reports (23, 24) . Myeloperoxidase (MPO) cDNA was provided by Dr. P. Koeffler (UCLA School of Medicine, Los Angeles, CA; ref. 25) . Glyceraldehyde-3-phosphate dehydrogenase cDNA was obtained from Ambion (Austin, TX). The probes were labeled with [a 32 P]dCTP by random priming to a specific activity of 0.5 to 1 Â 10 9 cpm/Ag. The membranes were prehybridized for 4 hours at 42jC in 50% formamide, 6Â saline-sodium phosphate-EDTA, 5Â Denhardt's reagent, and 0.2 mg/mL ssDNA, and hybridized with radiolabeled probe.
Apoptosis analysis. Apoptotic cells stained with acridine orange and ethidium bromide were assessed by fluorescence microscopy. Briefly, 1 AL of stock solution containing 100 Ag/mL acridine orange and 100 Ag/mL ethidium bromide were added to 25 AL of cell suspension. Total cells, as well as apoptotic cells that showed nuclear shrinkage, blebing, and apoptotic bodies, were counted. DNA fragmentation analysis was done as previously described (26) .
Results
Identification of compounds that enhance differentiation of all-trans retinoic acid-primed NB4-c cells. Based on our previous report (15), we developed a rapid screening assay to assess the effectiveness of compounds to enhance ATRAinduced differentiation in NB4-c cells. NB4-c cells, primed for 1 hour with 0.5 Amol/L ATRA and washed, show minimal differentiation induction (<10%) as measured by the NBT assay after 48 hours in culture. A 4-fold induction of differentiation was shown upon the addition of 2 mmol/L HMBA to the ATRAprimed NB4-c cells (15) . A subset of compounds (371) were selected from the NCI compound library, based on a cytostatic profile, defined as maintenance of multilog activity between 30% and 60% growth inhibition in the NCI 60 cell line, 48-hour screening assay. These were compared with HMBA as a positive control and evaluated for enhancement of ATRA-induced cell differentiation. No correlation was found between extent of toxicity and degree of enhanced differentiation among the treatment by these compounds because most compounds were inactive in this screening assay (<20%) regardless of toxicity (Fig. 1) . Several compounds enhanced ATRA-induced cell differentiation with 40% to 70% growth inhibition but without significant cytotoxicity (Fig. 1) ; however, those selected for further study reflect those without restriction and with a replenishable supply.
To validate the rapid screening assay, we selected 20 compounds for a blinded, more extensive 3-and 5-day study of drug-induced differentiation by NBT assay, and cytotoxicity using trypan blue exclusion. The differentiation enhancers identified in the initial screening assay were confirmed in these more detailed studies, thus validating the screening assay. Three compounds, NSC653643, NSC635748, and NSC144168 (structures are shown in Fig. 2) , exhibited similar or greater differentiation than that by the positive control, HMBA (Table 1 ). This differentiationenhancing effect was not associated with significant cell death as measured by trypan blue (data not shown). These active compounds were significantly more potent than HMBA, requiring Amol/L rather than the 2 mmol/L concentration needed for HMBA. Differentiation induction in NB4-c cells by NSC656243 was comparable with HMBA and most effective at 5 Amol/L, 635748 at 150 Amol/L, and 144168 at 20 Amol/L. There was minimal differentiation induction in the absence of ATRA priming and it is consistent with reports that ATRA is needed for differentiation induction of NB4 cells (15) . HMBA is a powerful differentiation inducer of mouse erythroleukemia and human HL-60 leukemia cells at concentration of 2 to 4 mmol/L (27, 28) . The three selected compounds are also capable of inducing partial murine erythroleukemia and HL-60 cell differentiation with minimal toxicity at lower concentrations than that required for HMBA (Table 1) .
Dose-dependent effect of NSC656243, a benzodithiophene, on NB4-c, HL-60, and murine erythroleukemia cell differentiation. Because NSC656243, a benzodithiophene compound, enhanced ATRA-primed NB4-c cells to undergo differentiation at 400-fold lower concentrations than that of HMBA and 3-to 30-fold lower than that of NSC144168 and NSC625748 (Table 1) , it was selected for further study. The dose-dependent effect of NSC656243 on induction of differentiation and cytotoxicity was studied in the three cell lines. As shown in Fig. 3A, NSC656243 at a concentration of below 5 Amol/L did not inhibit cell growth but induced <10% differentiation in NB4-c cells. When the cells were primed with 0.5 Amol/L ATRA followed by 1 to 5 Amol/L NSC656243, minimal cell growth inhibition was found without cell death (>90% of the cells alive), and 80% NBT-positive cells were detected in this sequential treatment (Fig 3B ) . Similarly, NSC656243 also enhanced the induction of differentiation in ATRA-primed parental NB4 cells. (Fig. 3C) . Unlike NB4-c and HL-60 cells, murine erythroleukemia cells were less sensitive to NSC656243-induced growth inhibition. NSC656243 at 20 Amol/L induced 40% of murine erythroleukemia cells to undergo erythroid differentiation with 20% cell growth inhibition without cell death (Fig. 3D) . NSC656243 enhances all-trans retinoic acid-dependent gene induction. The effect of NSC656243 on ATRA-up-regulated gene expression was studied in NB4-c cells after cotreatment with ATRA (0.5 Amol/L) in combination with NSC656243 (5 Amol/L), because enhancement of differentiation was similar to ATRA priming followed by NSC656243 (29) . As shown in Fig. 4 , the known ATRA-responsive genes RIG-E and RIG-G were weakly induced by treatment with ATRA alone and not by NSC656243 alone. A synergistic induction was found with the combined treatment. MPO is a down-regulated gene during ATRA induction of differentiated NB4 cells (25) . In NB4-c cells, ATRA or NSC656243 alone weakly down-regulated MPO expression, but the downregulation was synergized by the combination treatments (Fig. 4) . The cell cycle-and differentiation-related proteins (p21 waf1 , p27 KIP1 , and retinoblastoma) were evaluated in NB4-c cells after ATRA plus NSC656243 treatment and were weakly induced by treatment with ATRA or NSC656243 alone, whereas strong sustained induction was found with their combined treatment (Fig. 5) . The response to the drug combination was also associated with retinoblastoma hypophosphorylation (Fig. 5) . According to these data, it seems that ATRA-inducible gene expression is minimal by NSC656243 alone but is enhanced by combinatorial treatment in NB4-c cells. Thus, ATRA, but not nonretinoid chemical inducers, plays a critical role in the differentiation program of NB4 cells as reported (15) .
NSC656243 induces apoptosis in NB4-c and HL-60 cells. NSC656243, at 2-fold higher concentrations than the optimal concentration used to enhance ATRA differentiation, induced NB4-c and HL-60 cells to undergo cell death with the morphologic features of apoptosis. The induction of apoptosis is time and dose dependent (Fig. 6 ). NSC656243 at 5 Amol/L concentration, which induced 83% differentiation of NB4-c cells in combination with ATRA (Table 1) , induced <10% of NB4-c cell to undergo apoptosis. However, NSC656243 at 10 Amol/L induced 70% apoptosis in NB4-c cells after 48 hours treatment. HL-60 cells were less sensitive than NB4-c cells to NSC656243-induced apoptosis. NSC656243 at 10 Amol/L only induced 10% apoptosis in HL-60 cells, whereas 20 Amol/L induced nearly the same amount of apoptosis in both NB4-c and HL-60 cells. A time-dependent study indicated that NSC656243 at 10 Amol/L induced 15%, 58%, and 82% of apoptotic NB4-c cells after 1, 2, and 3 days treatment. However, at the same concentrations, NSC656243 induced 5%, 12%, and 25% apoptotic HL-60 cells after 1, 2, and 3 days treatment (Fig. 6 ). NSC656243-induced apoptosis in NB4-c cells was confirmed by assay of DNA fragmentation and activation of caspase-3 as detected by PARP cleavage. Bcl-2 protein levels were not influenced by NSC656243 treatment (Fig. 7) .
Antioxidants and Bcl-2 inhibited NSC656243-induced apoptosis. NB4-c cells were reported to be sensitive to apoptosis induced by agents that produce reactive oxygen species (30) . NSC656243 contains a quinone structure that predicts an ability to produce reactive oxygen species. Antioxidants were used to evaluate the role of reactive oxygen species in NSC656243-induced apoptosis. N-acetylcysteine blocked NSC656243-induced apoptosis in NB4-c cells (Fig. 8A) . Similarly, pyrrolidine dithiocarbamate, another antioxidant, inhibited NSC656243-induced apoptosis in NB4-c cells (Fig. 8B) . To test the role of Bcl-2 in NSC656243-induced apoptosis, HL-60/Bcl-2 cells with forced Bcl-2 overexpression (Fig. 8D) were used to compare the NSC656243-induced apoptosis with vector alone-transfected cells. NSC656243 at 20 Amol/L induced 70% apoptosis of HL-60/neo cells, but only 20% apoptosis of HL-60/Bcl-2 cells after 2 days treatment (Fig. 8C) .
Benzodithiophene structural relationship to differentiation. Derivatives of NSC656243 with modifications of carboxyl acid group and ketone group were used to determine benzodithiophene moieties required for enhancement of differentiation and/or apoptosis. 
Discussion
APL t(15;17) with PML-RARa fusion protein is the only human cancer that has successfully undergone complete remission through induction of differentiation (31) . PML-RARa is a dominant-negative receptor blocking RARa-mediated hematopoeitic cell differentiation (32) . Transcriptionally repressed RARa involves binding of nuclear corepressors, adaptor proteins, and recruitment of histone deacetylase. Physiologic ATRA binding to RARa releases the corepressors and leads to recruitment of cocoactivator proteins and activates gene transcription (7, 8) . PML-RARa, the APL oncogenic protein, binds the nuclear corepressor SMRT and N-CoR tightly through a nuclear corepressor (CoR) binding site located in the RARa moiety and requires pharmacologic ATRA concentrations to dissociate nuclear corepressors from PML-RARa protein and initiate transcription (33) (34) (35) (36) . This action has been thought to be the mechanism whereby pharmacologic ATRA concentrations induce APL cell differentiation. Theoretically, agents that facilitate the release or block the activity of corepressors will enhance ATRAmediated gene induction and cell differentiation. Indeed, it has been found that inhibitors of histone deacetylase, such as sodium butyrate and trichostatin A, synergize ATRA-mediated differentiation by overcoming PML-RARa transcriptional repression in APL cells and in one APL patient in relapse and resistant to ATRA treatment was successfully treated by the addition of sodium phenylbutyrate (10) (11) (12) (13) . Thus, the combination of ATRA with inhibitors of histone deacetylase may provide a powerful treatment for APL. However, the high therapeutic concentrations , and p27 kip1 protein levels.
of these agents may limit their therapeutic effect in vivo and new agents that can enhance/synergize ATRA-induced differentiation need to be identified. NSC656243, NSC625748, and NSC144168 enhanced ATRA-triggered differentiation at or below Amol/L concentrations with modest cytotoxicity (Table 1) , thus qualifying as potential agents for combinatorial treatment of APL with ATRA. Enhanced induction of differentiation occurs in NB4-c cells treated with butyrate or HMBA after ATRA priming (8, 15) . In contrast, differentiation is not enhanced in NB4-c cells primed with butyrate or HMBA then followed by ATRA (15) . These observations support the critical role of ATRA in overcoming PML-RARa transcriptional repression. Butyrate, but not HMBA, induces global histone acetylation; however, both agents enhance ATRA-induced gene transcription and differentiation (37) . In contrast to butyrate, but similar to HMBA, the compounds selected through the screen do not affect global histone acetylation (38) . Consistent with this, NSC656243 does not inhibit purified histone deacetylase activity, which is inhibited by butyrate using an in vitro assay (38) . This suggests that NSC656243 enhances ATRA-mediated cell differentiation by a histone deacetylase inhibition-independent pathway. However, we have not excluded site-specific gene promoter histone acetylation modulated by NSC656243. Because NSC656243 could induce partial differentiation in HL-60 and murine erythroleukemia cells, which do not contain the PML-RARa translocation (Table 1 and Fig. 3) , the enhanced effect of NSC656243 on ATRAmediated differentiation in NB4-c cells may be by a pathway unrelated to PML-RARa transcriptional repression. NSC656243 alone induces 10% NB4-c cell differentiation, weakly increases p21 waf1 protein, and decreases MPO mRNA levels (Figs. 4 and 5) . The partial differentiation effect observed may result from enhancement by NSC656243 on physiologic factors, such as ATRA or granulocyte colony-stimulating factor, triggered cell differentiation.
When the NSC656243 concentration is doubled, marked cytotoxicity with features of apoptosis is observed (Figs. 6 and 7) . Moreover, NB4-c cells are more sensitive than HL-60 cells to NSC656243-induced apoptosis (Fig. 6 ). This is similar to arsenic trioxide (As 2 O 3 )-induced apoptosis in both cell lines (30) . The finding of PARP cleavage indicates that activation of caspase-3 is involved in NSC656243-induced apoptosis (Fig. 7) . Antioxidants, such as N-acetylcysteine and pyrrolidine dithiocarbamate, block NSC656243-induced apoptosis (Fig. 8) , suggesting that reactive oxygen species production may mediate the process. NSC656243 and derivatives synergize or induce reactive oxygen speciesmediated apoptosis in several solid tumor cell lines, including melanoma (39) and pancreatic cancer (40) . Forced expression of Bcl-2, an inhibitor of reactive oxygen species-mediated apoptosis (41) , decreased extent of apoptosis in NSC656243-treated HL-60/ Bcl-2 cells (Fig. 8) .
NSC656243 is a benzodithiophene that contains a quinone structure ( Fig. 9; refs. 16, 17) . A derivative with a reduced quinone structure (NSC682994) at 10 nmol/L enhances ATRA-induced differentiation in NB4-c cells, making it the most potent derivative. However, it requires severalfold higher concentrations to induce apoptosis (data not shown). Thus, an intact quinone structure seems to be required for induction of apoptosis but not for induction of differentiation. ATRA is required for benzodithiophene-enhanced differentiation but not apoptosis of NB4-c cells (data not shown). Therefore, it seems that benzodithiophene enhancement of differentiation and induction of apoptosis occurs by a concentration-dependent activation of at least two independent pathways.
In summary, we find that several compounds from the NCI, Developmental Therapeutics repository, NSC656243, NSC625748, and NSC144168, induce leukemia cell differentiation by enhancing ATRA-mediated gene transcription at low concentrations and induce apoptosis at higher concentrations, which seems to involve reactive oxygen species production. The sensitivity of APL cells to the dual effects of benzodithiophenes (i.e., differentiation at low concentrations and apoptosis induction at higher concentrations) implies that benzodithiophenes might be potent agents for treatment of leukemia alone or in combination with ATRA.
